Clinical Trial Update: A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update indicates the APG-2575 study for breast cancer and solid tumors (Phase 1/Phase 2) has been suspended by sponsor Ascentage Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumor

Drugs mentioned

• APG-2575

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Breast Cancer, Solid Tumor, Adult | Phase 1, Phase 2 | Status: SUSPENDED